Nerve damage can be detected in the eye of a patient with Type 2 diabetes

Newest sensors open door to wearable medical diagnostic device

Automatically control insulin levels

Novel USB stick for HIV detection

The flash card for the rapid blood test for HIV was developed by researchers from Imperial College in London. Most of the 39 million individuals infected with HIV-1 live in sub-Saharan Africa in countries with limited infrastructure for healthcare delivery. Scientists came up with the novel approach to HIV-1 viral load detection based on a novel CMOS chip platform that is able to detect small changes in pH generated by on-chip reactions. The chip has embedded heaters and thermal sensors that facilitate on-chip nucleic acid amplification, and the hydrogen ions produced during DNA.

by
22 days ago

New eyes screening method can tell you if you are diabetic

The researchers' group from India has applied machine learning technique for diagnosing diabetes (lat. Diabetes Mellitus). The precision of this technique is 89.63% and its specificity and sensitivity are 0.9687 and 0.988 respectively. Scientists are going to create the portable device applying artificial intelligence that will provide a non-invasive method of diabetes detection. Furthermore, it is cheap and easy to use making it appropriate for applying by a non-medical practitioner effectively.

by
22 days ago

Custom-made microbes

It became possible to design with synthetic biology using DNA codes for programming microbes of yeast. This technology inspired by renewable natural processes was developed by Ginkgo Bioworks’ scientists with MIT pickaback. This custom microbe programming opens the possibilities to make all kinds of products such as cosmetics, fragrances, food ingredients, sweeteners, medicines and even to grow electronics by replacing their DNA with the customised one.

by
22 days ago

Lens that can measure bodily functions

Innovative therapy to restore brain function

Discovery that may lead to lower doses of chemotherapy

Avalon AI accelerates the development of a cure for aging

Avalon AI uses Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. The company also provides handy 2D and 3D visualizations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences. Avalon AI is currently running trials with select clinics in India, Pakistan and Ukraine. Their founding mission is to accelerate the development of a cure for aging. Of all the diseases of old age, neurodegenerative diseases like Alzheimer's (lat. Morbus Alzheimerianus) are the most terrifying. They gradually rob identity and dignity. Yet, as a population is aging, a third of them will end lives with a neurodegenerative disease.

by
22 days ago

Dimension Therapeutics develops novel gene therapies for severe genetic disorders

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. The company's team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. Dimension Therapeutics is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in haemophilia ( lat. Hemophilia), and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. 

by
22 days ago

Freeline Therapeutics: a next-generation proprietary AAV platform technology

Freeline Therapeutics is a leading clinical-stage biotechnology company that focuses on the development and commercialisation of innovative gene therapies. The company is aimed to create better lives for people suffering from chronic, debilitating disease. Freeline Therapeutics is developing functional cures for a wide range of liver-based diseases, such as haemophilia B ( lat. Hemophilia) and Fabry, which have previously been underserved and incurable. The company's gene therapy builds on the renowned pioneering work of the founder and CSO, Amit Nathwani, Professor of Haematology at the University College London (UCL). In addition, Freeline Therapeutics has raised £88.4M in Series B funding.

by
22 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM